Pyrazole-amide compounds and pharmaceutical use thereof

1. A compound represented by the formula [I]:

wherein n is 1 or 2,

or a pharmaceutically acceptable salt thereof.

2. A compound represented by the formula:

3. The compound according to claim 2 , which is represented by the formula [II]:

4. The compound according to claim 2 , which is represented by the formula [IIh]:

5. A compound represented by the formula [III]:

6. A pharmaceutical composition comprising the compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A method for inhibiting PDHK in a mammal comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, to the mammal.

8. A method for inhibiting PDHK1 in a mammal comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, to the mammal.

9. A method for inhibiting PDHK2 in a mammal comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, to the mammal.

10. A method for decreasing the blood glucose level in a mammal comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, to the mammal.

11. A method for decreasing lactate level in a mammal comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, to the mammal.

12. A method for the treatment of diabetes, insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications, cardiac failure, cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer or pulmonary hypertension in a mammal, comprising administering a pharmaceutically effective amount of the compound according to any one of claims 1 to 5 , or a pharmaceutically acceptable salt thereof, to the mammal.

13. The method according to claim 12 , wherein the diabetes is type 1 diabetes or type 2 diabetes.

14. The method according to claim 12 , wherein the diabetic complications are selected from the group consisting of diabetic neuropathy, diabetic retinopathy, diabetic nephropathy and cataract.

15. The method according to claim 12 , wherein the cardiac failure is acute cardiac failure or chronic cardiac failure.

16. The method according to claim 13 , wherein the diabetes is type 2 diabetes.